In a report released today, Richard Vosser from J.P. Morgan maintained a Buy rating on Sanofi, with a price target of €105.00. The company’s shares closed yesterday at $95.03.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Vosser covers the Healthcare sector, focusing on stocks such as Roche Holding AG, Novo Nordisk, and Sanofi. According to TipRanks, Vosser has an average return of 2.1% and a 47.10% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Sanofi with a $121.67 average price target, representing a 28.03% upside. In a report released on October 8, Guggenheim also maintained a Buy rating on the stock with a €101.00 price target.
The company has a one-year high of $123.67 and a one-year low of $88.80. Currently, Sanofi has an average volume of 56.79K.
Read More on SNYNF:
Disclaimer & DisclosureReport an Issue
- Sanofi’s New COPD Treatment Study: A Potential Game-Changer?
- Sanofi’s Promising COPD Study: Lunsekimig’s Potential Impact
- Trump Weekly: Generics to be excluded from pharma tariff plan
- Sanofi’s New Study on SAR446597: A Potential Game-Changer for Age-related Macular Degeneration
- Trump Trade: GoodRx, others in talks with White House to join TrumpRx
/A%20Lucid%20Motors%20vehicle%20parked%20in%20front%20of%20a%20showroom_%20Image%20by%20Michael%20Berlfein%20via%20Shutterstock_.jpg)
/Broadcom%20Inc%20logo%20on%20phone%20and%20site-by%20Majahid%20Mottakin%20via%20Shutterstock.jpg)
/Tesla%20Inc%20logo%20by-%20baileystock%20via%20iStock.jpg)
